Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

Sermorelin research overview

Sermorelin is the amidated 1–29 fragment of human growth-hormone-releasing hormone (GHRH), generally studied through the pituitary GHRH receptor.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is Sermorelin acetate?

Controlled human studies have used GHRH(1-29)-amide as an endocrine stimulus and measured acute or repeated growth-hormone and IGF-I responses.

Research category

Endocrine & receptor signaling

Study models represented

Controlled human endocrine-response studies

Names in the literature

GHRH(1-29)-NH2; GRF(1-29)-amide

Primary boundary

Acute or protocol-specific hormone changes do not establish broad clinical outcomes.

What does the selected evidence support?

Hormone-response tests and historical clinical research do not establish general anti-aging, body-composition, or performance claims.

Primary sources

1. Wilton et al., Clinical Endocrinology (1993) — GHRH(1-29)-amide endocrine-response study in healthy men. DOI: 10.1111/j.1365-2265.1993.tb02392.x
2. Corpas et al., JCEM (1992) — Repeated GHRH(1-29) study in growth-hormone-deficient children and young adults. DOI: 10.1210/jcem.75.2.1379256

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review Sermorelin acetate product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.